Benefits and risks: What does the current data say?

Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of baricitinib, abrocitinib and upadacitinib with reference to the EMA opinion on JAK-i issued some time ago. In the EU, baricitinib has now been given an extended indication for AD patients aged 2 years and older.